NEW YORK, July 18 (GenomeWeb News) - Genaissance Pharmaceuticals and Organon will jointly study genetic markers related to drug response in certain undisclosed psychiatric disorders, and plan to develop diagnostics based on the resulting data, the companies said today.
Under the agreement, Organon will license Genaissance's HAP technology and will pay the company fees for genotyping samples from clinical trials and for research. Genaissance will also provide DNA isolation and sample banking for the trials.
In addition to providing services, Genaissance has certain rights to develop and commercialize genetic tests accompanying therapy. Both companies will share royalties on revenues generated from such tests.
Organon, a business unit of Akzo Nobel, is based in